



CHARCOT-MARIE-TOOTH DISEASE

RMA ID Number	Reference List for RMA087-3 as at August 2023
---------------	---

40244	Access Medicine (2006). Charcot-Marie-Tooth Disease. Retrieved 6 September 2006, from http://www.accessmedicine.com/popup.aspx?aID=108056&print=yes
110757	Anandh U, Nikalji R, Parick A (2018). Membranous nephropathy in a patient with Charcot-Marie-Tooth disease: association of myelin mutations. <i>Indian J Nephrol</i> , 28(5): 397-400.
41430	Anderson DM, Keith J, Novak PD (Lexicographers) (2003). <i>Dorland's Illustrated Medical Dictionary</i> , 30th Edition, WB Saunders, Philadelphia.
102516	Australian Medicines Handbook (2021). Amiodarone. Retrieved 12 October 2021, from https://amhonline.amh.net.au/chapters/cardiovascular-drugs/drugs-arrhythmias/antiarrhythmics/amiodarone
109673	Australian Medicines Handbook (2022). Arsenic trioxide. Retrieved 11 January 2023, from https://amhonline.amh.net.au
109676	Australian Medicines Handbook (2022). Auranofin. Retrieved 11 January 2023, from https://amhonline.amh.net.au
110745	Australian Medicines Handbook (2022). Bortezomib. Retrieved 22 March 2023, from https://amhonline.amh.net.au/chapters/immunomodulators-antineoplastics/cytotoxic-antineoplastics/proteasome-inhibitors/bortezomib?menu=hints
109677	Australian Medicines Handbook (2022). Brentuximab vedotin. Retrieved 11 January 2023, from https://amhonline.amh.net.au
109679	Australian Medicines Handbook (2022). Carboplatin. Retrieved 11 January 2023, from https://amhonline.amh.net.au
110746	Australian Medicines Handbook (2022). Cetuximab. Retrieved 22 March 2023, from https://amhonline.amh.net.au/chapters/immunomodulators-antineoplastics/non-cytotoxic-antineoplastics/antineoplastic-antibodies/cetuximab
109682	Australian Medicines Handbook (2022). Cisplatin. Retrieved 11 January 2023, from https://amhonline.amh.net.au
109683	Australian Medicines Handbook (2022). Colchicine. Retrieved 11 January 2023, from https://amhonline.amh.net.au
109686	Australian Medicines Handbook (2022). Dapsone. Retrieved 11 January 2023, from https://amhonline.amh.net.au
109688	Australian Medicines Handbook (2022). Disulfiram. Retrieved 11 January 2023, from https://amhonline.amh.net.au
109691	Australian Medicines Handbook (2022). Eribulin. Retrieved 11 January 2023, from https://amhonline.amh.net.au
109700	Australian Medicines Handbook (2022). Ipilimumab. Retrieved 11 January 2023, from https://amhonline.amh.net.au
109702	Australian Medicines Handbook (2022). Leflunomide. Retrieved 11 January 2023, from https://amhonline.amh.net.au

110747	Australian Medicines Handbook (2022). Lenalidomide. Retrieved 22 March 2023, from https://amhonline.amh.net.au/chapters/immunomodulators-antineoplastics/non-cytotoxic-antineoplastics/thalidomide-analogues/lenalidomide
110748	Australian Medicines Handbook (2022). Linezolid. Retrieved 22 March 2023, from https://amhonline.amh.net.au/chapters/anti-infectives/antibacterials/other-antibacterials/linezolid
109706	Australian Medicines Handbook (2022). Metronidazole. Retrieved 11 January 2023, from https://amhonline.amh.net.au
110750	Australian Medicines Handbook (2022). Nitrofurantoin. Retrieved 22 March 2023, from https://amhonline.amh.net.au/chapters/anti-infectives/antibacterials/other-antibacterials/nitrofurantoin
109707	Australian Medicines Handbook (2022). Nitrous oxide. Retrieved 11 January 2023, from https://amhonline.amh.net.au
110749	Australian Medicines Handbook (2022). Nivolumab. Retrieved 22 March 2023, from https://amhonline.amh.net.au/chapters/immunomodulators-antineoplastics/non-cytotoxic-antineoplastics/antineoplastic-antibodies/nivolumab
110752	Australian Medicines Handbook (2022). Oxaliplatin. Retrieved 22 March 2023, from https://amhonline.amh.net.au/chapters/immunomodulators-antineoplastics/cytotoxic-antineoplastics/platinum-compounds/oxaliplatin
110751	Australian Medicines Handbook (2022). Pembrolizumab. Retrieved 22 March 2023, from https://amhonline.amh.net.au/chapters/immunomodulators-antineoplastics/non-cytotoxic-antineoplastics/antineoplastic-antibodies/pembrolizumab
109708	Australian Medicines Handbook (2022). Perhexiline. Retrieved 11 January 2023, from https://amhonline.amh.net.au
109711	Australian Medicines Handbook (2022). Pomalidomide. Retrieved 11 January 2023, from https://amhonline.amh.net.au
110754	Australian Medicines Handbook (2022). Pyridoxine. Retrieved 22 March 2023, from https://amhonline.amh.net.au/chapters/antidotes-antivenoms/antidotes/pyridoxine
110753	Australian Medicines Handbook (2022). Quinolones. Retrieved 22 March 2023, from https://amhonline.amh.net.au/chapters/anti-infectives/antibacterials/quinolones
109667	Australian Medicines Handbook (2022). Tacrolimus. Retrieved 11 January 2023, from https://amhonline.amh.net.au
110755	Australian Medicines Handbook (2022). Taxanes. Retrieved 22 March 2023, from https://amhonline.amh.net.au/chapters/immunomodulators-antineoplastics/cytotoxic-antineoplastics/taxanes
109718	Australian Medicines Handbook (2022). Thalidomide. Retrieved 11 January 2023, from https://amhonline.amh.net.au
110756	Australian Medicines Handbook (2022). Vinca alkaloids. Retrieved 22 March 2023, from https://amhonline.amh.net.au/chapters/immunomodulators-antineoplastics/cytotoxic-antineoplastics/vinca-alkaloids
109723	Australian Medicines Handbook (2022). Vincristine. Retrieved 11 January 2023, from https://amhonline.amh.net.au
110758	Budure AN, Winqvist E, Palma D, et al (2019). Successful treatment of nasopharyngeal cancer using radiotherapy with concurrent cetuximab in a patient with Charcot-Marie-Tooth disease. <i>BMJ Case Rep</i> , 12(7): e228956.
40247	Charcot-Marie-Tooth Association (2006). An overview of Charcot-Marie-Tooth disorders. Retrieved 6 September 2006, from http://www.charcot-marie-tooth.org/about_cmt/overview.php

110759	Charcot-Marie-Tooth Association (CMTA) (2023). Neurotoxic medications. Retrieved 22 March 2023, from https://www.cmtausa.org/living-with-cmt/managing-cmt/medications/
40252	Chauvenet AR, Shashi V, Selsky C, et al (2003). Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth disease in acute lymphoblastic leukemia: a pediatric oncology group study. <i>J Pediatr Hematol Oncol</i> , 25(4): 316-20.
71744	Cruse RP (2014). Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease. Retrieved 10 June 2014, from http://www.uptodate.com/contents/hereditary-primary-motor-sensory-neuropathies-including-charcot-marie-tooth-disease?source=search_result&search=Hereditary+primary+motor+sensory+neuropathies%2C+including+Charcot-Marie-Tooth+disease&selectedTitle=1%7E150
110760	Dorland's Medical Dictionary Online (2022). Charcot-Marie-Tooth disease. Retrieved 21 December 2022, from https://www.dorlandsonline.com/dorland/definition?id=70175
40250	Hildebrandt G, Holler E, Woenkhaus M, et al (2000). Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2mg of vincristine chemotherapy. <i>Ann Oncol</i> , 11(6): 743-7.
71745	Isbister GK, Burns J, Prior F, et al (2008). Safety of nitrous oxide administration in patients with Charcot-Marie-Tooth disease. <i>J Neurol Sci</i> , 268: 160-2.
110762	Kang PB (2022). Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis. Retrieved 22 March 2023, from https://www.uptodate.com/contents/charcot-marie-tooth-disease-genetics-clinical-features-and-diagnosis
110761	Kang PB (2022). Charcot-Marie-Tooth disease: management and prognosis. Retrieved 22 March 2023, from https://www.uptodate.com/contents/charcot-marie-tooth-disease-management-and-prognosis
40245	Kedlaya D (2005). Charcot-Marie-Tooth Disease. Retrieved 6 September 2006, from http://www.emedicine.com/orthoped/section~introduction#section~introduction
110763	Kikukawa Y, Hata H, Ueda M, et al (2016). Successful treatment of amyloid light-chain amyloidosis in a Charcot-Marie-Tooth disease patient with lenalidomide, cyclophosphamide, and dexamethasone. <i>Intern Med</i> , 55(18): 2707-12.
40390	Martino MA, Miller E, Grendys EC Jr (2005). The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer. <i>Gynecol Oncol</i> , 97(2): 710-2.
109732	Micromedex (2022). Arsenic trioxide. Adverse effects. Retrieved 12 January 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
109741	Micromedex (2022). Colchicine. Adverse effects. Retrieved 12 January 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
109746	Micromedex (2022). Didanosine. Adverse effects. Retrieved 12 January 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
109761	Micromedex (2022). Ixabepilone. Adverse effects. Retrieved 12 January 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
109763	Micromedex (2022). Lenalidomide. Adverse effects. Retrieved 12 January 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
109764	Micromedex (2022). Linezolid. Adverse effects. Retrieved 12 January 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
109770	Micromedex (2022). Nitrofurantoin. Retrieved 12 January 2023, from https://www.micromedexsolutions.com/micromedex2/librarian

109776	Micromedex (2022). Stavudine. Adverse effects. Retrieved 12 January 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
109778	Micromedex (2022). Suramin. Overview. Retrieved 12 January 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
109779	Micromedex (2022). Tacrolimus. Adverse effects. Retrieved 12 January 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
109785	Micromedex (2022). Zalcitabine. Adverse effects. Retrieved 12 January 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110764	Micromedex (2023). Amiodarone. Adverse effects. Retrieved 22 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110765	Micromedex (2023). Auranofin. Adverse effects. Retrieved 22 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110766	Micromedex (2023). Bortezomib. Adverse effects. Retrieved 22 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110769	Micromedex (2023). Brentuximab vedotin. Adverse effects. Retrieved 22 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110767	Micromedex (2023). Carboplatin. Adverse effects. Retrieved 22 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110770	Micromedex (2023). Cetuximab. Adverse effects. Retrieved 22 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110771	Micromedex (2023). Ciprofloxacin. Adverse effects. Retrieved 22 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110768	Micromedex (2023). Cisplatin. Adverse effects. Retrieved 22 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110773	Micromedex (2023). Dapsone. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110774	Micromedex (2023). Disulfiram. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110776	Micromedex (2023). Eribulin. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110777	Micromedex (2023). Ipilimumab. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110775	Micromedex (2023). Leflunomide. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110778	Micromedex (2023). Metronidazole. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110779	Micromedex (2023). Nitrous oxide. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110783	Micromedex (2023). Nivolumab. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110780	Micromedex (2023). Oxaliplatin. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110781	Micromedex (2023). Paclitaxel. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110784	Micromedex (2023). Pembrolizumab. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110782	Micromedex (2023). Perhexiline maleate. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/
110789	Micromedex (2023). Pomalidomide. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110785	Micromedex (2023). Pyridoxine. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
110786	Micromedex (2023). Sodium dichloroacetate. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/
110787	Micromedex (2023). Thalidomide. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian

110788	Micromedex (2023). Vincristine. Adverse effects. Retrieved 23 March 2023, from https://www.micromedexsolutions.com/micromedex2/librarian
40248	Muscular Dystrophy Australia (2006). Fact sheet: Charcot-Marie-tooth disease. Retrieved 6 September 2006, from http://www.mda.org.au/specific/mdacmt.html
40246	National Institute of Neurological Disorders and Stroke (NINDS) (2006). Charcot-Marie-Tooth disease information page. Retrieved 6 September 2006, from http://www.ninds.nih.gov/disorders/charcot_marie_tooth/charcot_marie_tooth.htm
40249	National Institute of Neurological Disorders and Stroke (NINDS) (2006). Charcot-Marie-Tooth disease fact sheet. Retrieved 6 September 2006, from http://www.ninds.nih.gov/disorders/charcot_marie_tooth/detail_charcot_marie_tooth.htm
40251	Naumann R, Mohm J, Reuner U, et al (2001). Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. <i>Br J Haematol</i> , 115(2): 323-5.
40253	Orejana-Garcia AM, Pascual-Huerta J, Perez-Melero A (2003). Charcot-Marie-Tooth disease and vincristine. <i>J Am Podiatr Med Assoc</i> , 93(3): 229-33.
71746	Weimer LH, Podwall D (2006). Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. <i>J Neurol Sci</i> , 242: 47-54.